Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy. There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors.
The global market for Gene Therapy Viral Vector and Plasmid DNA was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Gene Therapy Viral Vector and Plasmid DNA was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gene Therapy Viral Vector and Plasmid DNA was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Gene Therapy Viral Vector and Plasmid DNA was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Gene Therapy Viral Vector and Plasmid DNA include Lonza, Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories, Catalent, WuXi AppTec, FUJIFILM, GenScript Biotech and Takara Bio, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gene Therapy Viral Vector and Plasmid DNA, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Gene Therapy Viral Vector and Plasmid DNA by region & country, by Type, and by Application.
The Gene Therapy Viral Vector and Plasmid DNA market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy Viral Vector and Plasmid DNA.
麻豆原创 Segmentation
By Company
Lonza
Merck KGaA
Thermo Fisher Scientific
Charles River Laboratories
Catalent
WuXi AppTec
FUJIFILM
GenScript Biotech
Takara Bio
Oxford Biomedica
Novartis
Precision Biosciences
Bluebird Bio
Sartorius AG
Danaher
SIRON Biotech
VGXI
Waisman Biomanufacturing
Kaneka Eurogentec
PlasmidFactory
ATUM
Addgene
Cell and Gene Therapy Catapult
Batavia biosciences
Altogen Biosystems
Segment by Type:
Viral Vectors
Plasmid DNA
Segment by Application
Cell and Gene Therapy
Vaccine Development
Research
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gene Therapy Viral Vector and Plasmid DNA manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Gene Therapy Viral Vector and Plasmid DNA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Gene Therapy Viral Vector and Plasmid DNA in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 Gene Therapy Viral Vector and Plasmid DNA Product Introduction
1.2 Global Gene Therapy Viral Vector and Plasmid DNA 麻豆原创 Size Forecast
1.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value (2019-2030)
1.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume (2019-2030)
1.2.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Price (2019-2030)
1.3 Gene Therapy Viral Vector and Plasmid DNA 麻豆原创 Trends & Drivers
1.3.1 Gene Therapy Viral Vector and Plasmid DNA Industry Trends
1.3.2 Gene Therapy Viral Vector and Plasmid DNA 麻豆原创 Drivers & Opportunity
1.3.3 Gene Therapy Viral Vector and Plasmid DNA 麻豆原创 Challenges
1.3.4 Gene Therapy Viral Vector and Plasmid DNA 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Gene Therapy Viral Vector and Plasmid DNA Players Revenue Ranking (2023)
2.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Company (2019-2024)
2.3 Global Gene Therapy Viral Vector and Plasmid DNA Players Sales Volume Ranking (2023)
2.4 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Company Players (2019-2024)
2.5 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Company (2019-2024)
2.6 Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Gene Therapy Viral Vector and Plasmid DNA
2.9 Gene Therapy Viral Vector and Plasmid DNA 麻豆原创 Competitive Analysis
2.9.1 Gene Therapy Viral Vector and Plasmid DNA 麻豆原创 Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Gene Therapy Viral Vector and Plasmid DNA Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy Viral Vector and Plasmid DNA as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Viral Vectors
3.1.2 Plasmid DNA
3.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type
3.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value, by Type (2019-2030)
3.2.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value, by Type (%) (2019-2030)
3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Type
3.3.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume, by Type (2019-2030)
3.3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume, by Type (%) (2019-2030)
3.4 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cell and Gene Therapy
4.1.2 Vaccine Development
4.1.3 Research
4.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application
4.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value, by Application (2019-2030)
4.2.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value, by Application (%) (2019-2030)
4.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Application
4.3.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume, by Application (2019-2030)
4.3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume, by Application (%) (2019-2030)
4.4 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Region
5.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Region (2019-2024)
5.1.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Region (2025-2030)
5.1.4 Global Gene Therapy Viral Vector and Plasmid DNA Sales Value by Region (%), (2019-2030)
5.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Region
5.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Region (2019-2024)
5.2.3 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Region (2025-2030)
5.2.4 Global Gene Therapy Viral Vector and Plasmid DNA Sales Volume by Region (%), (2019-2030)
5.3 Global Gene Therapy Viral Vector and Plasmid DNA Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
5.4.2 North America Gene Therapy Viral Vector and Plasmid DNA Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
5.5.2 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
5.6.2 Asia Pacific Gene Therapy Viral Vector and Plasmid DNA Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
5.7.2 South America Gene Therapy Viral Vector and Plasmid DNA Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
5.8.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Gene Therapy Viral Vector and Plasmid DNA Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Gene Therapy Viral Vector and Plasmid DNA Sales Value
6.2.1 Key Countries/Regions Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
6.2.2 Key Countries/Regions Gene Therapy Viral Vector and Plasmid DNA Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
6.3.2 United States Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
6.4.2 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
6.5.2 China Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type (%), 2023 VS 2030
6.5.3 China Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
6.6.2 Japan Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
6.7.2 South Korea Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
6.8.2 Southeast Asia Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Gene Therapy Viral Vector and Plasmid DNA Sales Value, 2019-2030
6.9.2 India Gene Therapy Viral Vector and Plasmid DNA Sales Value by Type (%), 2023 VS 2030
6.9.3 India Gene Therapy Viral Vector and Plasmid DNA Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Lonza
7.1.1 Lonza Company Information
7.1.2 Lonza Introduction and Business Overview
7.1.3 Lonza Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Lonza Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.1.5 Lonza Recent Development
7.2 Merck KGaA
7.2.1 Merck KGaA Company Information
7.2.2 Merck KGaA Introduction and Business Overview
7.2.3 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.2.5 Merck KGaA Recent Development
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Company Information
7.3.2 Thermo Fisher Scientific Introduction and Business Overview
7.3.3 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.3.5 Thermo Fisher Scientific Recent Development
7.4 Charles River Laboratories
7.4.1 Charles River Laboratories Company Information
7.4.2 Charles River Laboratories Introduction and Business Overview
7.4.3 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.4.5 Charles River Laboratories Recent Development
7.5 Catalent
7.5.1 Catalent Company Information
7.5.2 Catalent Introduction and Business Overview
7.5.3 Catalent Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Catalent Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.5.5 Catalent Recent Development
7.6 WuXi AppTec
7.6.1 WuXi AppTec Company Information
7.6.2 WuXi AppTec Introduction and Business Overview
7.6.3 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.6.4 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.6.5 WuXi AppTec Recent Development
7.7 FUJIFILM
7.7.1 FUJIFILM Company Information
7.7.2 FUJIFILM Introduction and Business Overview
7.7.3 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.7.4 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.7.5 FUJIFILM Recent Development
7.8 GenScript Biotech
7.8.1 GenScript Biotech Company Information
7.8.2 GenScript Biotech Introduction and Business Overview
7.8.3 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.8.4 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.8.5 GenScript Biotech Recent Development
7.9 Takara Bio
7.9.1 Takara Bio Company Information
7.9.2 Takara Bio Introduction and Business Overview
7.9.3 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.9.5 Takara Bio Recent Development
7.10 Oxford Biomedica
7.10.1 Oxford Biomedica Company Information
7.10.2 Oxford Biomedica Introduction and Business Overview
7.10.3 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.10.5 Oxford Biomedica Recent Development
7.11 Novartis
7.11.1 Novartis Company Information
7.11.2 Novartis Introduction and Business Overview
7.11.3 Novartis Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Novartis Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.11.5 Novartis Recent Development
7.12 Precision Biosciences
7.12.1 Precision Biosciences Company Information
7.12.2 Precision Biosciences Introduction and Business Overview
7.12.3 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.12.5 Precision Biosciences Recent Development
7.13 Bluebird Bio
7.13.1 Bluebird Bio Company Information
7.13.2 Bluebird Bio Introduction and Business Overview
7.13.3 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.13.5 Bluebird Bio Recent Development
7.14 Sartorius AG
7.14.1 Sartorius AG Company Information
7.14.2 Sartorius AG Introduction and Business Overview
7.14.3 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.14.5 Sartorius AG Recent Development
7.15 Danaher
7.15.1 Danaher Company Information
7.15.2 Danaher Introduction and Business Overview
7.15.3 Danaher Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Danaher Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.15.5 Danaher Recent Development
7.16 SIRON Biotech
7.16.1 SIRON Biotech Company Information
7.16.2 SIRON Biotech Introduction and Business Overview
7.16.3 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.16.4 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.16.5 SIRON Biotech Recent Development
7.17 VGXI
7.17.1 VGXI Company Information
7.17.2 VGXI Introduction and Business Overview
7.17.3 VGXI Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.17.4 VGXI Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.17.5 VGXI Recent Development
7.18 Waisman Biomanufacturing
7.18.1 Waisman Biomanufacturing Company Information
7.18.2 Waisman Biomanufacturing Introduction and Business Overview
7.18.3 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.18.5 Waisman Biomanufacturing Recent Development
7.19 Kaneka Eurogentec
7.19.1 Kaneka Eurogentec Company Information
7.19.2 Kaneka Eurogentec Introduction and Business Overview
7.19.3 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.19.4 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.19.5 Kaneka Eurogentec Recent Development
7.20 PlasmidFactory
7.20.1 PlasmidFactory Company Information
7.20.2 PlasmidFactory Introduction and Business Overview
7.20.3 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.20.4 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.20.5 PlasmidFactory Recent Development
7.21 ATUM
7.21.1 ATUM Company Information
7.21.2 ATUM Introduction and Business Overview
7.21.3 ATUM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.21.4 ATUM Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.21.5 ATUM Recent Development
7.22 Addgene
7.22.1 Addgene Company Information
7.22.2 Addgene Introduction and Business Overview
7.22.3 Addgene Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.22.4 Addgene Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.22.5 Addgene Recent Development
7.23 Cell and Gene Therapy Catapult
7.23.1 Cell and Gene Therapy Catapult Company Information
7.23.2 Cell and Gene Therapy Catapult Introduction and Business Overview
7.23.3 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.23.4 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.23.5 Cell and Gene Therapy Catapult Recent Development
7.24 Batavia biosciences
7.24.1 Batavia biosciences Company Information
7.24.2 Batavia biosciences Introduction and Business Overview
7.24.3 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.24.4 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.24.5 Batavia biosciences Recent Development
7.25 Altogen Biosystems
7.25.1 Altogen Biosystems Company Information
7.25.2 Altogen Biosystems Introduction and Business Overview
7.25.3 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue and Gross Margin (2019-2024)
7.25.4 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product Offerings
7.25.5 Altogen Biosystems Recent Development
8 Industry Chain Analysis
8.1 Gene Therapy Viral Vector and Plasmid DNA Industrial Chain
8.2 Gene Therapy Viral Vector and Plasmid DNA Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Gene Therapy Viral Vector and Plasmid DNA Sales Model
8.5.2 Sales Channel
8.5.3 Gene Therapy Viral Vector and Plasmid DNA Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Lonza
Merck KGaA
Thermo Fisher Scientific
Charles River Laboratories
Catalent
WuXi AppTec
FUJIFILM
GenScript Biotech
Takara Bio
Oxford Biomedica
Novartis
Precision Biosciences
Bluebird Bio
Sartorius AG
Danaher
SIRON Biotech
VGXI
Waisman Biomanufacturing
Kaneka Eurogentec
PlasmidFactory
ATUM
Addgene
Cell and Gene Therapy Catapult
Batavia biosciences
Altogen Biosystems
听
听
*If Applicable.
